180 results about "High glucose" patented technology

The invention relates to the technical field of industrial microorganisms, and particularly discloses a yeast strain and application thereof. The invention provides clavipora lusitaniae YJHT233, which is obtained through space mutation breeding, can tolerate 9% of alcohol, can tolerate an acid environment with the lowest pH value of 2.5, can tolerate a 12% high NaCl system, a 55% high glucose system and a 44 DEG C high temperature environment, and has excellent ester production capacity. The strain is used for brewing rice-flavor liquor or yellow wine, the total content of ester substances in the obtained product is greatly increased, the content of main volatile ester substances such as ethyl acetate, ethyl butyrate, isoamyl acetate, ethyl caprylate and ethyl lactate is remarkably increased, the whole flavor is coordinated and pleasant, and the fruit fragrance is rich and rich in layers.

The invention relates to the technical field of biological pharmacy, in particular to application of a recombinant protein DEL-1 in preparation of a medicine for resisting pancreatic beta cell inflammation. The recombinant protein DEL-1 has a remarkable inhibition effect on pancreatic beta cell inflammatory response induced by high glucose and high fat. Experiments show that in an islet beta cell inflammation model constructed by combining high glucose with palmitic acid, DEL-1 can significantly reduce the expression level of inflammatory factors such as IL-1beta, IL-6, TNF-alpha and the like. The DEL-1 is proved to have a definite effect of resisting pancreatic beta cell inflammation.

The invention provides a bismuth-based heterogeneous material for promoting healing of diabetic wounds and a preparation method and application thereof. The bismuth-based heterogeneous material comprises a bismuth-based porphyrin metal organic framework, and the surface of the bismuth-based porphyrin metal organic framework is modified with Au-Pt nanoparticles. According to the bismuth-based heterogeneous material disclosed by the invention, microenvironments of bacterial infection, high glucose, active oxygen damage, inflammatory disorder, pH rise and oxygen deficit of diabetic wounds are improved through multiple antibacterial effects and enzyme catalysis effects, so that the healing of the diabetic wounds is promoted.

The invention discloses a cane molasses extract with a blood sugar reducing effect as well as a preparation method and application thereof, and belongs to the field of functional foods. According to the invention, cane molasses is subjected to dissolution, centrifugation, ultrafiltration impurity removal, desalination and nanofiltration concentration, and is mixed with calcium chloride, so that the cane molasses extract with the effect of reducing blood sugar is prepared. Experimental results prove that the cane molasses extract prepared by the invention has the characteristics of low glycemic index (GI), carbohydrate digestive enzyme inhibition, high temperature resistance, long-term storage resistance and the like, can also effectively repair pancreas and liver injury and regulate intestinal flora, and has a comprehensive hypoglycemic effect. The food with low glycemic index is prepared on the basis of the high sucrose carrier for the first time, and the food has sweet taste and the function of reducing blood sugar. The invention provides a new raw material scheme for the preparation of dietary supplement food and hypoglycemic drugs for hyperglycemia people, and has prominent practical application value and wide application prospect.

The invention belongs to the technical field of assisted reproduction, and particularly relates to a glucose slow-release structure used in an embryo in-vitro culture solution, a preparation process and a use method. The glucose slow-release structure comprises at least one inner layer containing glucose and a biodegradable material outer layer wrapping the inner layer, and the biodegradable material outer layer comprises a matrix with a plurality of micropores and at least one sealing material layer used for sealing pores of the micropores. According to the invention, gradient release from low sugar in the cleavage stage to high sugar in the blastocyst stage is realized, midway liquid change or artificial sugar supplement is not needed, the operation is obviously simplified, and pollution and mechanical stress risks are reduced.

The application discloses a kind of glucose oxidase sensors based on modified multi-walled carbon nanotube modification, it is related to glucose oxidase sensor technical field, including the following steps: (1) modified multi-walled carbon nanotube preparation;(2) glassy carbon electrode is carried out surface polishing treatment;(3) obtain modified multi-walled carbon nanotube dispersion;(4) obtain glucose oxidase liquid;(5) glucose glucose oxidase liquid impregnation electrode;(6) using Nafion solution covers electrode;The sensor obtained after the electrode is modified by introducing modified multi-walled carbon nanotube in the application, not only has higher glucose detection sensitivity, but also has excellent stability.

The invention discloses application of selazinomethyl ether and a pharmaceutical composition thereof in preparation of a medicine for preventing or treating brain injury. The invention provides the application of selazine methyl ether in preparing the medicine for preventing or treating the brain injury for the first time, and selazine methyl ether has a remarkable effect in preventing or treating the brain injury, especially cerebral arterial thrombosis and the brain injury caused by hemorrhagic transformation of the cerebral arterial thrombosis. And cerebral injury caused by cerebral arterial thrombosis and hemorrhagic transformation can be obviously relieved. According to the application disclosed by the invention, the sefoazinomethyl ether has the effects of remarkably reducing the cerebral infarction area and behavioral scoring under the condition of middle cerebral artery occlusion; the selobezine methyl ether has the effects of remarkably reducing the hemorrhage area, hemorrhage score and behavioral score under acute high glucose and middle cerebral artery occlusion; the pharmaceutical composition containing selazine methyl ether can become a novel drug for preventing or treating brain injury, and can be used for treating various cerebrovascular diseases including cerebral arterial thrombosis and hemorrhagic transformation of cerebral arterial thrombosis.

The invention discloses an in-vivo blood glucose monitoring system based on microgel response characteristics, which is characterized by improving a microgel synthesis process, accurately characterizing physical properties and response characteristics of a material, optimizing the design of an implanted microgel sensor and constructing an electromagnetic detection module based on dielectric constant measurement. Accurate, real-time and continuous monitoring of the in-vivo blood glucose level is achieved. The system overcomes the problems of large trauma, discontinuous data, insufficient long-term stability, high cost and the like of a traditional blood drawing method by utilizing the remarkable volume and dielectric constant change of microgel under the conditions of low blood sugar and high blood sugar, and has the remarkable advantages of high sensitivity, quick response and long-term stability; a brand new technical scheme is provided for precise management of metabolic diseases such as diabetes, and the technical scheme also has a wide application prospect in other biomedical monitoring fields.

The present invention discloses a polyporus badius polysaccharide and its preparation method and application, belonging to the technical field of polysaccharide extraction. The polyporus badius polysaccharide (PPP-0A) includes galactose, fucose, glucose, mannose and xylose, and the molar ratios are 62.26%, 16.96%, 15.23%, 4.68% and 0.87% respectively. The present invention uses techniques such as methylation, scanning electron microscopy, thermogravimetric analysis, nuclear magnetic resonance and atomic force microscopy to determine the structural characteristics of PPP-0A, analyze its composition and properties, and its inhibitory effects on the activities of α-glucosidase and α-amylase. In addition, an in vitro HepG2 cell model induced by high blood glucose and high insulin levels was used to study the hypoglycemic effect of PPP-0A. The present invention provides a theoretical basis for clarifying the relationship between the hypoglycemic activity of PPP-0A and its hypoglycemic effect on type 2 diabetic mice.

The invention belongs to the field of new application of medicines, and particularly relates to application of triptolide in preparation of medicines for treating diabetic vascular obstruction complications. Diabetes vascular obstruction is a common serious complication of diabetes and can cause various tissue injuries such as cardiovascular diseases, nephropathy and retinopathy. Experiments prove that the triptolide can remarkably improve the problems of blood vessel blockage, blood flow slowing, abnormal neovascularization and the like caused in a high-glucose environment, and meanwhile, the expression of blood glucose related indexes (such as Glucose and HbA1c) and inflammatory factors (such as TNF-alpha and IL-1beta) is reduced. In addition, triptolide can also protect pancreas from high glucose damage and improve functions of pancreatic beta cells. According to the invention, the clinical application range of the triptolide is expanded, and a new candidate substance is provided for drug treatment of diabetic vascular complications.

The present invention discloses applications and methods of Leuconostoc mesenteroides, relating to the field of microbial technology. Leuconostoc mesenteroides can be used to prepare phytic acid and improve non-alcoholic fatty liver disease, increased liver weight, elevated blood lipids, elevated blood sugar, elevated serum lipopolysaccharide levels, elevated serum insulin levels, inflammatory responses, and elevated triglyceride levels in the liver caused by a high-fat, high-sugar diet, and inhibit the release of the pro-inflammatory cytokine lipopolysaccharide.

The invention relates to the technical field of medicines, in particular to application of a recombinant protein DEL-1 in preparation of a medicine for resisting pancreatic beta cell senescence. Within the concentration range of 400-1000 ng / ml, the DEL-1 can reduce the high glucose and high fat induced pancreatic beta cell SA-beta-Gal positive rate by 39.5% or above, and the anti-aging effect is remarkable.

An auricular stimulation device having surface electrodes biased towards each other, and offset from one another, is provided. The stimulation device can be positioned about the ear of a patient with each of the electrodes overlaying auricular ear tissue containing innervation supplied by an auricular branch of the vagus nerve. The electrodes transcutaneously stimulate the auricular branch. Also provided is a method of treating a patient using the auricular stimulation device. The stimulation device can be used for treating patients with conditions such as high blood pressure, depression, high blood glucose level, and tinnitus. Also provided is a diagnostic and therapeutic system having the auricular stimulation device, a smart device and a monitoring device. The smart device controls the auricular stimulation device based on biomarker information received from the monitoring device; and on information related to the patient, such as age, musculoskeletal stability, etc.; and / or on user input.

Disclosed is recombinant Escherichia coli for producing L-tyrosine and application thereof, and belongs to the technical fields of genetic engineering and bioengineering. According to the present disclosure, genes aroP and tyrP are knocked out, expresses the endogenous gene yddG of E. coli, then heterologously expresses fpk from Bifidobacterium adolescentis, expresses the endogenous genes ppsA and tktA of E. coli, and then expresses aroGfbr and tyrAfbr. Knocking out tyrR, trpE and pheA, so that the synthesis flux of L-tyrosine is increased. Finally, an endogenous gene poxB is knocked out to realize stable fermentation performance at high glucose concentration.

The present invention relates to a biocompatible tattoo ink that changes color in response to varying glucose levels in the bloodstream, providing a continuous monitoring method for individuals with diabetes. The ink contains glucose-sensitive agents that cause the tattoo to change from green (normal glucose levels) to red (high glucose levels) or blue (low glucose levels). Additionally, the ink shifts back to green when blood glucose returns to normal from either hyperglycemia or hypoglycemia. This provides a real-time visual indicator of glucose levels and enables users to monitor their health without additional equipment.

The invention belongs to the technical field of biology, and relates to agrobacterium capable of resisting high glucose and producing curdlan at high yield and application of the agrobacterium in curdlan production. The Agrobacterium is radioactive Agrobacterium sp. LQC24G-08, and is preserved in the China Center for Type Culture Collection on February 24, 2025, the address is Wuhan University, Wuhan, China, and the preservation number is CCTCC NO: M 2025287. The Agrobacterium has the advantages that the Agrobacterium is used for culturing the Agrobacterium; when the agrobacterium provided by the invention is used for fermentation production of curdlan, the fermentation process is simple, the fermentation yield of the curdlan is higher, and the agrobacterium has high sugar tolerance and is beneficial to industrial application.

Provided are various embodiments relating to a GLP1R agonist or a dual agonist that specifically binds canine, feline, and / or equine GLP1R, or Glucagon receptor / G1PR. Such agonists can be used alone or in combination in methods to treat canine, feline, and / or equine metabolic disorders, such as high glucose, obesity, osteoarthritis, improved cardiovascular outcomes, and for the extension of healthy aging.

Metabolic dysfunction–associated steatotic liver disease (MASLD), previously known as non- alcoholic fatty liver disease (NAFLD), is a condition characterized by the accumulation of fat in the liver of individuals with no alcohol consumption, and at least one cardiometabolic risk factor (overweight / obesity, high blood pressure, high blood sugar, high triglycerides levels, low HDL-C levels). The inventors demonstrated that Rab30 silencing improve metabolic dysfunction–associated steatotic liver disease (MASLD). The present invention relates to a method for the treatment of metabolic dysfunction–associated steatotic liver disease (MASLD) in a subject in need thereof comprising the administration of a therapeutically effective amount of an inhibitor of Rab30.

The application discloses a kind of recombinant escherichia coli for producing L-tyrosine and application, belong to genetic engineering and bioengineering technical field.The application knocks out aroP and tyrP gene, expresses the yddG gene of escherichia coli endogenous to modify the aromatic amino acid transport system of escherichia coli, then heterologous expression comes from bifidobacterium fpk and expresses the ppsA and tktA gene of escherichia coli endogenous to increase the precursor supply of shikimic acid pathway, again through the anti feedback gene expression aroG and tyrA 3-deoxy-D-arabino-heptulosonic acid-7-phosphate synthetase, branch acid mutase and prephenate dehydrogenase are removed feedback inhibition, increase the carbon flux of shikimic acid pathway.Knock out tyrR gene removes the repression of TyrR protein to shikimic acid pathway key enzyme, again knock out trpE and pheA gene to block partial side reaction of shikimic acid pathway, so that the synthesis flux of L-tyrosine increases.Finally knock out endogenous poxB gene to realize the modification of acetic acid pathway, realizes the stable fermentation performance of high glucose concentration.

The application provides application of circ-0007527 as a target in screening of drugs for treating peritoneal dialysis related peritoneal fibrosis. The application also provides application of an inhibitor of circ-0007527 in preparation of a drug for treating peritoneal dialysis related peritoneal fibrosis. In a mouse peritoneal fibrosis model induced by high glucose peritoneal dialysis solution, circRNA expressed in peritoneal tissues is screened, and after bioinformatics analysis, it is found that the differential expression amount of circ-0007527 in the fibrotic peritoneal tissue is the highest, and the high expression of circ-0007527 in the fibrotic peritoneal tissue is verified by real-time fluorescent quantitative PCR. Further in-vitro cell experiments find that down-regulation of the expression of circ-0007527 can significantly inhibit peritoneal mesothelial cell phenotype transformation, proliferation and apoptosis, and thus reduce peritoneal injury and delay peritoneal fibrosis progression.

This invention provides the application of glucose-responsive nanohydrogels in the preparation of drugs for treating skin injuries. The method includes the following steps: mixing hyaluronic acid with a phenylboronic acid compound, adding 3-aminophenylboronic acid, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride and N-hydroxysuccinimide, and performing a grafting reaction to obtain boric acid-modified hyaluronic acid; adding myricetin-3-O-galactoside, phospholipids, and cholesterol to an organic solvent, followed by thin-film hydration and ultrasonic treatment to obtain nanoliposomes; mixing the boric acid-modified hyaluronic acid with a polyvinyl alcohol solution, then adding the nanoliposome solution, and finally mixing to obtain the resulting nanohydrogel. The glucose-responsive nanohydrogel of this invention achieves adaptive drug release in the high glucose environment of diabetic wounds and regulates local metabolic homeostasis of the wound, especially the lysine degradation pathway in amino acid metabolism.

An active Fano resonance blood glucose sensor, relating to the field of non-invasive blood glucose monitoring. The blood glucose sensor comprises a resonator, an excitation layer, a low-noise amplifier (8) and a phase shifter (9), wherein the resonator, the low-noise amplifier (8) and the phase shifter (9) form a connection loop; the resonator is provided on the excitation layer; and the excitation layer is connected to an external excitation source. By using the phase shifter (9), the phase of an active circuit can be changed to selectively enhance resonance, improve the resonance Q factor, and realize detection of minor changes in blood glucose concentration, and thus the active Fano resonance blood glucose sensor can be applied to human blood glucose sensing and the problems in the prior art of poor stability and robustness. Moreover, by using the resonator and the excitation layer, self-reference error elimination can be achieved, significantly improving the performance of the microwave blood glucose sensor and improving the reliability of blood glucose measurement.

The invention belongs to the field of blood glucose detection, and relates to a high-sensitivity blood glucose noninvasive detection method and system based on polarized terahertz photoacoustic, which combines the advantages of terahertz wave band detection and photoacoustic detection, fully utilizes the chiral characteristics of glucose molecules, and adopts polarized terahertz photoacoustic to detect the blood glucose concentration. Polarization optical rotation change information is extracted through the time domain photoacoustic signal; by selecting the characteristic absorption wave band of glucose and utilizing the difference between glucose and other blood components in chiral characteristics, the influence of water and other high-concentration ions on terahertz signals is remarkably reduced, so that the selectivity and the anti-interference capability of blood glucose detection are effectively improved; terahertz non-ionizing radiation is adopted as an excitation source, no ionizing injury risk is caused to a human body, and the device is suitable for long-term repeated detection and is expected to be popularized and applied in wearable or bedside monitoring equipment.

Disclosed is a blood glucose measurement device capable of improving blood glucose measurement accuracy by focusing rays of light for blood glucose measurement in the measurement area of an object. According to an embodiment of the present invention, the blood glucose measurement device comprises: a light source unit disposed to output a plurality of first light rays for measuring blood glucose in the measurement area of an object; an optical unit including one or more optical bodies disposed to emit a plurality of first light rays toward the measurement area of the object; and a light-receiving unit disposed to receive a plurality of second light rays output through an interaction between the plurality of first light rays and the object. The one or more optical bodies include: a plurality of lenses arranged to condense a plurality of first light rays on the first surface of one or more optical bodies facing the light source unit; a reflective surface arranged to reflect a plurality of first light rays condensed by the plurality of lenses on the second surface of one or more optical bodies; and a refractive surface arranged to refract a plurality of first light rays reflected at the reflective surface toward the measurement area of the object on the third surface of one or more optical bodies.

The present invention provides a method to identify and use compounds for the inhibition of abnormal or dysregulated hepatic glucose production that results in elevated blood glucose levels and associated metabolic disorders. The invention is based on the surprising discovery that the glucagon forms an obligate binding complex with aP2, which is necessary for activation of the glucagon G-coupled protein receptor.

The invention discloses a method for preparing monosaccharide from lignocellulose biomass and acid circulation, which comprises the following steps of: (1) performing swelling reaction on the lignocellulose biomass by using more than 70 weight percent of inorganic acid solution to obtain high-acid biomass candy pomace; (2) extracting the obtained high-acid biomass candy pomace with an organic solvent to obtain low-acid biomass candy pomace and an acid-containing organic phase; and (3) adding the low-acid biomass candy pomace into water and / or an acid solution to prepare a mixed solution with the acid concentration of below 30wt%, and carrying out hydrolysis reaction to obtain a reaction solution containing monosaccharide. The process provided by the invention not only can effectively solve the problems, including invalid degradation of carbohydrates, small molecular byproducts and complex and harsh reaction conditions, existing in the process of preparing sugar from lignocellulose, but also can effectively improve the acid recovery rate while keeping relatively high glucose yield and xylose yield.

Disclosed is an application of a Lycium barbarum leaf extract in preparing a drug for treating diabetic retinopathy. According to the invention, a refined Lycium barbarum leaf extract is prepared by specific process steps, and active ingredients of Lycium barbarum leaf can protect ARPE-19 cells from high glucose-induced damage, have a certain improvement effect on zebrafish with diabetic retinopathy, and significantly improve eye symptoms in a diabetic retinopathy mouse model. The Lycium barbarum leaf extract provided by the invention has the potential to be a drug for treating diabetic retinopathy.

The invention discloses a preparation method of dendrobium officinale polysaccharide-based dual-responsive drug-release hydrogel, and relates to a preparation method of drug-release hydrogel. The invention aims to solve the problem of difficult healing of diabetic wounds. The preparation method comprises the following steps: firstly synthesizing hyaluronic acid-3-aminophenylboronic acid, connecting the hyaluronic acid-3-aminophenylboronic acid with resveratrol, and finally doping the hyaluronic acid-3-aminophenylboronic acid with dendrobium candidum polysaccharide-1, 4-butanediol diglycidyl ether-sodium polyacrylate, so as to prepare the dendrobium candidum polysaccharide-1, 4-butanediol diglycidyl ether / hyaluronic acid-3-aminophenylboronic acid-resveratrol hydrogel. The borate bond in the hydrogel can be broken in a high glucose or high active oxygen environment, so that the responsive release of the active substance resveratrol is realized. The prepared hydrogel has the characteristics of being injectable, self-healing and very sensitive to the pathological environment responding to diabetic wounds, can effectively inhibit the ROS level in cells and regulate and control M2 polarization of macrophages, and has an obvious proliferation effect on fibroblasts, so that wound gap closure is promoted, and the healing time of the wounds is shortened.

The present application provides a Pichia pastoris engineering bacterium and a kit and application thereof, a method for obtaining the Pichia pastoris engineering bacterium, a method for improving glucose oxidase yield of the Pichia pastoris, and a method for producing glucose oxidase, wherein the Pichia pastoris engineering bacterium carries a glucose oxidase gene and a pyruvate kinase gene. The Pichia pastoris engineering bacterium of the present application can realize high glucose oxidase yield and high enzyme activity, and lays a good foundation for large-scale production of glucose oxidase.

The invention relates to the technical field of biology, in particular to application of SAFit2 in preparation of a reagent for improving pancreas islet dysfunction. The invention discovers that SAFit2 has a remarkable improvement effect on insulin secretion dysfunction in a high-glucose and high-fat induced islet injury model. Experiments show that in a high glucose (33 mM) combined palmitic acid (500 [mu] M) injury model, the SAFit2 can significantly improve the insulin secretion function of the pancreas islet. Specifically, the SAFit2 is pretreated, the glucose stimulated insulin secretion (GSIS) index of the pancreas islet and the intracellular insulin content are remarkably increased, insulin secretion under high glucose stimulation is promoted, and the SAFit2 is proved to have the effect of promoting the insulin secretion function of the pancreas islet beta cells.